Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Joseph M. Connors,Wojciech Jurczak,David J. Straus,Stephen M. Ansell,Won Kim,Andrea Gallamini,Anas Younes,Sergey Alekseev,Árpád Illés,Marco Picardi,Ewa Lech-Marańda,Yasuhiro Oki,Tatyana Feldman,Piotr Smolewski,Kerry J. Savage,Nancy L. Bartlett,Jan Walewski,Robert T. Chen,Radhakrishnan Ramchandren,Pier Luigi Zinzani,David Cunningham,András Rosta,Neil C Josephson,Eric Song,Jessica A. Sachs,Rachael Liu,Hina Jolin,Dirk Huebner,John Radford +28 more
Reads0
Chats0
TLDR
A+AVD had superior efficacy to ABVD in the treatment of patients with advanced‐stage Hodgkin's lymphoma, with a 4.9 percentage‐point lower combined risk of progression, death, or noncomplete response and use of subsequent anticancer therapy at 2 years.Abstract:
Background Brentuximab vedotin is an anti-CD30 antibody–drug conjugate that has been approved for relapsed and refractory Hodgkin’s lymphoma. Methods We conducted an open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin’s lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 670 were assigned to receive doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The primary end point was modified progression-free survival (the time to progression, death, or noncomplete response and use of subsequent anticancer therapy) as adjudicated by an independent review committee. The key secondary end point was overall survival. Results At a median follow-up of 24.6 months, 2-year modified progression-free survival rates in the A+AVD and ABVD groups were 82.1% (95% confidence interval [CI], 78.8 to 85.0) and 77.2% (95% CI, 73.7 to 80.4), respectively, a difference of...read more
Citations
More filters
Journal ArticleDOI
Cancer treatment and survivorship statistics, 2022
Kimberly D. Miller,Leticia Nogueira,Theresa P Devasia,Angela B. Mariotto,K. Robin Yabroff,Ahmedin Jemal,Joan L. Kramer,Rebecca L. Siegel +7 more
TL;DR: Estimation of cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries, vital statistics from the Centers for Disease Control and Prevention’s National Center for Health Statistics, and population projections from the US Census Bureau finds that more than 18 million Americans with a history of cancer were alive on January 1, 2022.
Journal ArticleDOI
Antibody-Drug Conjugates: A Comprehensive Review
TL;DR: This review provides an overview of the systemic evaluation of each component of an ADC design, improved understanding of the mechanism of action of ADC, and mechanistic pathways involved in ADC resistance and various strategies to optimize ADC design.
Journal ArticleDOI
Antibody–drug conjugates for cancer
TL;DR: Recent clinical experience with the approved ADCs and other promising late-stage candidates on the horizon are reviewed, following an overview of the biology and chemistry of ADCs.
Journal ArticleDOI
Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
TL;DR: The ADC field continues to evolve, including ongoing efforts aimed at improving target selection, developing payloads with varied mechanisms of action and increased potency, designing innovative bioconjugation strategies, as well as maximizing efficacy and tolerability in patients.
Journal ArticleDOI
Ultrasound-Activated Sensitizers and Applications
TL;DR: This review provides summary, discussion and inspiration of the types of novel sonosensitizers developed in the last few years and outlines their specific designs and the potential challenges.
References
More filters
Journal ArticleDOI
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Martin M. Oken,Richard H. Creech,Douglass C. Tormey,John Horton,Thomas E. Davis,Eleanor T. McFadden,Paul P. Carbone +6 more
TL;DR: The Eastern Cooperative Oncology Group criteria for toxicity and response are presented to facilitate future reference and to encourage further standardization among those conducting clinical trials.
Journal ArticleDOI
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
TL;DR: The criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly are addressed, and the issue of borderline categories having overlapping features with large B-cell lymphomas is reviewed.
Journal ArticleDOI
A Prognostic Score for Advanced Hodgkin's Disease
Dirk Hasenclever,Volker Diehl +1 more
TL;DR: The prognostic score developed may be useful in designing clinical trials for the treatment of advanced Hodgkin's disease and in making individual therapeutic decisions, but a distinct group of patients at very high risk could not be identified on the basis of routinely documented demographic and clinical characteristics.
Journal ArticleDOI
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.
T. A. Lister,Derek Crowther,S B Sutcliffe,E Glatstein,George P. Canellos,Robert C. Young,Saul A. Rosenberg,C A Coltman,M Tubiana +8 more
TL;DR: It was concluded that the structure of the Hodgkin's disease classification be maintained and that a new category of response to therapy, unconfirmed/uncertain complete remission (CR[u]), be introduced to accommodate the difficulty of persistent radiological abnormalities of uncertain significance.
Related Papers (5)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes,Ajay K. Gopal,Scott E. Smith,Stephen M. Ansell,Joseph D. Rosenblatt,Kerry J. Savage,Radhakrishnan Ramchandren,Nancy L. Bartlett,Bruce D. Cheson,Sven de Vos,Andres Forero-Torres,Craig H. Moskowitz,Joseph M. Connors,Andreas Engert,Emily K. Larsen,Dana A. Kennedy,Eric L. Sievers,Robert T. Chen +17 more
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Peter Johnson,Massimo Federico,Amy A Kirkwood,Alexander Fosså,Leanne Berkahn,Angelo Michele Carella,Francesco d'Amore,Gunilla Enblad,Antonella Franceschetto,Michael J. Fulham,Stefano Luminari,Michael O'Doherty,Pip Patrick,Thomas Roberts,Gamal Sidra,L. Stevens,Paul Smith,Judith Trotman,Z. Viney,John Radford,Sally F. Barrington +20 more
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz,Auayporn Nademanee,Tamas Masszi,Edward Agura,Jerzy Holowiecki,Muneer H. Abidi,Andy I. Chen,Patrick J. Stiff,Alessandro M. Gianni,Angelo Michele Carella,Dzhelil Osmanov,Veronika Bachanova,John W. Sweetenham,Anna Sureda,Dirk Huebner,Eric L. Sievers,Andy Chi,Emily K. Larsen,Naomi N. H. Hunder,Jan Walewski +19 more
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Robert W. Chen,Pier Luigi Zinzani,Michelle A. Fanale,Philippe Armand,Nathalie A. Johnson,Pauline Brice,John Radford,Vincent Ribrag,Daniel Molin,Theodoros P. Vassilakopoulos,Akihiro Tomita,Bastian von Tresckow,Margaret A. Shipp,Yinghua Zhang,Alejandro D. Ricart,Arun Balakumaran,Craig H. Moskowitz +16 more
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell,Alexander M. Lesokhin,Alexander M. Lesokhin,Ivan Borrello,Ahmad Halwani,Emma C. Scott,Martin Gutierrez,Stephen J. Schuster,Michael Millenson,Deepika Cattry,Gordon J. Freeman,Scott J. Rodig,Bjoern Chapuy,Azra H. Ligon,Lili Zhu,Joseph F. Grosso,Su Y oung Kim,John M. Timmerman,Margaret A. Shipp,Philippe Armand +19 more